Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events

Marie Kostine (1) , Eleonora Mauric , Alice Tison , Thomas Barnetche , Aurélien Barre (2) , Macha Nikolski (3, 2) , Léa Rouxel , Caroline Dutriaux , Léa Dousset , Sorilla Prey , Marie Beylot-Barry , Julien Seneschal , Rémi Veillon , Charlotte Vergnenegre , Amaury Daste , Charlotte Domblides , Baptiste Sionneau , Marine Gross-Goupil , Alain Ravaud (1) , Edouard Forcade , Thierry Schaeverbeke (1)

1 CHU Bordeaux
2 CBIB - Centre de Bioinformatique de Bordeaux
3 IBGC - Institut de biochimie et génétique cellulaires

Domains: Bioinformatics [q-bio.QM]

Marie Kostine, Eleonora Mauric, Alice Tison, Thomas Barnetche, Aurélien Barre, et al.. Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. European Journal of Cancer, 2021, 157, pp.474-484. ⟨10.1016/j.ejca.2021.08.036⟩. ⟨hal-03671495⟩